Patent · US Active

Short interfering RNA (siRNA) analogues

US9738894B2 · kind B2 · utility

3Cited by

7References

27Claims

0Family size

Assignee

ROCHE INNOVATION CENTER COPENHAGEN A/S · DK

Inventors

Joacim Elmen · Stockholm, SE
Claes Wahlestedt · Palm Beach, US
Zicai Liang · Beijing, CN
Anders M. Sorensen · Thisted, DK
Henrik Orum · Frederikssund, DK
Troels Koch · Copenhagen, DK

Key dates

Filing date	Mar 28, 2016
Grant date	Aug 22, 2017
Priority date	—
Expiry date	Mar 28, 2036

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention is directed to novel double-stranded short interfering (siRNA) analogs comprising locked nucleic acid (LNA) monomers. Such compounds induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). The compounds disclosed herein has improved properties compared to non-modified siRNAs and may, accordingly, be useful as therapeutic agents, e.g., in the treatment of various cancer forms. More particularly, the present invention is directed to siRNA analogs comprising a sense strand and an antisense strand, wherein each strand comprises 12-35 nucleotides and wherein the siRNA analogs comprise at least one locked nucleic acid (LNA) monomer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.